Parkinson’s Disease Treatment Market to Reach $22.6 Billion by 2035

Parkinson’s disease treatment market was valued at $12.2 billion in 2025 and is projected to reach $22.6 billion by 2035, growing at a CAGR of 6.2% during the forecast period (2025–2035). Parkinson’s disease is a progressive neurological disorder that primarily affects movement control, with rising prevalence driven by aging populations globally. Treatment approaches include pharmacological therapies, device-based interventions, surgical procedures, and supportive non-pharmacological therapies aimed at improving patient quality of life. Pharmacological treatments remain the primary revenue driver of the market, particularly Levodopa + Carbidopa, which continues to be the gold standard for symptom management. Other widely used drug classes include dopamine agonists, MAO-B inhibitors, and COMT inhibitors, which are often used in combination therapies to enhance clinical outcomes. These medications help manage motor symptoms such as tremors, rigidity, and bradykinesia, thereby sustaining their dominant share in global revenues.

Browse the full report description of “Parkinson’s Disease Treatment Market Size, Share & Trends Analysis Report, By Treatment Type (Pharmacological Treatments, Device-Based Treatments, Surgical Procedures, and Non-Pharmacological Therapies), By Drug Class (Levodopa + Carbidopa, Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, and Other Drugs), By End User (Hospitals, Neurology Clinics, Ambulatory Surgical Centers, and Home Care Settings), Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/parkinsons-disease-treatment-market

A key macro driver accelerating market growth is the rapid increase in the aging population, which is highly susceptible to Parkinson’s disease. According to data from the World Health Organization (WHO), the global population aged 60 years and above is expected to nearly double from 1 billion in 2020 to 2.1 billion by 2050. Additionally, WHO estimates indicate that Parkinson’s disease prevalence has doubled over the past 25 years, with over 8.5 million individuals affected globally. This sharp rise in patient population is directly fueling demand for long-term treatment solutions, thereby supporting sustained market expansion. Among the segments, Device-Based Treatments, particularly Deep Brain Stimulation (DBS) under neuromodulation technologies, represent the fastest-growing category. DBS systems are gaining traction due to their effectiveness in managing advanced-stage Parkinson’s symptoms when pharmacological therapies become less effective. Technological advancements and increasing clinical adoption are driving this segment forward.

Furthermore, market players are actively implementing strategic initiatives to strengthen their positions. A few of the strategies are given below: -

• In March 2026, the US Food and Drug Administration (FDA) issued a safety update for Parkinson’s disease treatments, requiring manufacturers of drugs containing carbidopa and levodopa to include warnings about a potential risk of seizures linked to vitamin B6 deficiency.

• In October 2025, Mitsubishi Tanabe Pharma received a Complete Response Letter (CRL) from the US FDA regarding its New Drug Application (NDA) for ND0612. This investigational therapy is a 24-hour continuous subcutaneous infusion of liquid levodopa/carbidopa designed to reduce motor fluctuations. While the FDA raised observations regarding manufacturing sites and nonclinical information, the company remains committed to addressing these requirements to bring the first non-surgical continuous delivery system to the U.S. market.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Treatment Type
  • By Technology
  • By Drug Class
  • By End User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Medtronic plc, Lundbeck A/S, Acadia Pharmaceuticals, Mitsubishi Tanabe Pharma, Boston Scientific, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Parkinson’s Disease Treatment   Market Report Segment

By Treatment Type

• Pharmacological Treatments
• Device-Based Treatments
• Surgical Procedures (Non-device specific)
• Non-Pharmacological Therapies

By Drug Class

• Levodopa + Carbidopa
• Dopamine Agonists
• MAO-B Inhibitors
• COMT Inhibitors
• Other Drugs

By End User

• Hospitals
• Neurology Clinics
• Ambulatory Surgical Centers (ASCs)
• Home Care Settings

Global Parkinson’s Disease Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/parkinsons-disease-treatment-market